When Should Open-Label Extension Studies Be Stopped?

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.14, Iss.4, 2014-04, pp. : 57-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Open-Label Extension Studies: Are They Really Research?

By Cho Mildred K.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 60-61

Routledge Ltd

Access to resources Recommend Favorite

Ethics of Continuing to Provide a Drug on an Open-Label Extension Study for an “Unapproved Indication”

By Taylor Holly A. Kuwana Ellen Wilfond Benjamin S.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 56-56

Routledge Ltd

Access to resources Recommend Favorite

The Role of Clinical Equipoise and Practical Considerations in Deciding Whether to Continue to Provide a Drug on an Open-Label Extension Study for an “Unapproved Indication”

By Nash Ryan R.

American Journal of Bioethics, Vol. 14, Iss. 4, 2014-04 ,pp. : 59-60

Routledge Ltd

Access to resources Recommend Favorite

To Screen or Not to Screen:When Should Screening Be Offered?

Public Health Genomics, Vol. 1, Iss. 3, 1999-03 ,pp. : 145-147

Karger

Access to resources Recommend Favorite

When "Risk" and "Benefit" Are Open to Interpretation - As Is Generally the Case

By Spriggs Merle

American Journal of Bioethics, Vol. 7, Iss. 3, 2007-03 ,pp. : 17-19

Routledge Ltd

Access to resources Recommend Favorite